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A B S T R A C T
Background. Low birth weight (LBW) is associated with a
higher risk of end-stage renal disease (ESRD). The relative
impacts of absolute birth weight, birth weight in relation to ges-
tational age and preterm birth are, however, uncertain.
Methods. The Medical Birth Registry of Norway has since 1967
recorded data on all births. All patients with ESRD since 1980
have been registered in the Norwegian Renal Registry. Data
from these registries were linked. All individuals registered in
the Medical Birth Registry were included and the development
of ESRD was used as endpoint in Cox regression statistics. LBW
and LBW for gestational age [small for gestational age (SGA)]
according to the 10th percentiles were used as the main predic-
tor variables.
Results. Of the 2 679 967 included subjects, 1181 developed
ESRD. Compared with subjects without LBW, subjects with
LBW had an adjusted hazard ratio (aHR) for ESRD of 1.61
(1.38–1.98). SGA had an aHR of 1.44 (1.22– 1.70). Further anal-
yses showed that as compared with subjects who had none of
the risk factors LBW, SGA and preterm birth, subjects with one
risk factor had an aHR of 1.05 (0.84–1.31), subjects with two
risk factors had an aHR of 1.67 (1.40–1.98) and subjects with
three risk factors had an aHR of 2.96 (1.84–4.76).
Conclusions. We conclude that LBW was associated with in-
creased risk for ESRD during the first 50 years. Our analyses
add to previous knowledge showing that only subjects with at
least two of the risk factors LBW, SGA or preterm birth have in-
creased risk.
Keywords: CKD, ESRD, low birth weight, prematurity, small
for gestational age
I N T R O D U C T I O N
In 1988, Brenner et al. hypothesized that low birth weight
(LBW) might predispose for chronic kidney disease (CKD)
in adult age through a mechanism of impaired nephron
endowment in utero [1]. This hypothesis was later supported by
several studies, and measures of LBW have been associated
with increased risk of albuminuria, end-stage renal disease
(ESRD) and CKD [2]. Recent papers thus argue for screening
for kidney disease in subjects with LBW [2–4].
The World Health Organization (WHO) defines LBW as
birth weight <2500 g and several studies have confirmed that
this is associated with CKD and ESRD [2, 5–7]. Other measures
of LBW or preterm birth have also been associated with in-
creased risk, such as birth weight less than the 10th percentile,
gestational age <37 weeks and LBW for gestational age [small
for gestational age (SGA)] [5, 7–9]. A previous Norwegian
study showed that SGA might be more important than LBW in
adult patients and that preterm birth might further increase the
risk [7]. LBW could on the other hand be more strongly associ-
ated with ESRD before 18 years of age due to hereditary or de-
velopmental disorders [7, 8]. Based on the existing literature
there thus seems to be an important need for further studies of
the relative contributions of different markers of LBW as well as
a possible gender difference.
The Norwegian studies described above had investigated the
association between markers of LBW and risk of ESRD for
the first 38–42 years of life [7, 8]. In this study, we have linked
the Norwegian registries once more and the new data allowed
for follow-up until 50 years of age and a deeper analysis of the
relative contributions of LBW, SGA and preterm birth. We also
analysed different cut-offs for LBW and SGA as well as possible
gender differences. We hypothesized that LBW and SGA would
be associated with increased risk of ESRD and that preterm
birth and gender modify this risk.
M A T E R I A L S A N D M E T H O D S
Since 1967, extensive data on all births in Norway as well as ma-
ternal disease and conditions of the newborn have been regis-
tered in the Medical Birth Registry of Norway for all births of
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16 weeks gestation or more; data were available until the end of
2016. Since 1980, data (including date of onset and cause of
ESRD) on all patients developing ESRD (defined as starting
chronic dialysis treatment or undergoing renal transplantation)
have been registered in the Norwegian Renal Registry; data
were available until December 2016. The Norwegian
Population Registry has the registered date of death for all
inhabitants for the relevant period of time until 31 December
2016.
We included all individuals born alive in Norway between
1967 and 2016. We excluded twins, individuals who died before
age 1 year and individuals who died before 1980. Data were
recorded in the Medical Birth Registry of Norway and linked
with the Norwegian Renal Registry and the Norwegian
Population registry using the national identification number
(unique for each citizen and used by all administrative and
health services—offering a complete and exact linkage).
The study protocol was approved by the regional ethics com-
mittee with approval number 2017/627.
Explanatory variables
Birth weight was measured immediately after birth. LBW
was defined as birth weight less than the gender-specific 10th
percentile (2.94 kg for male and 2.85 kg for female). Preterm
birth was defined as gestational age <37 weeks. Based on gen-
der, gestational age and birth weight, z-score of birth weight for
gestational age has been calculated for all single births. SGA was
defined as birth weight less than the 10th percentile for gesta-
tional age using previously published gender-specific reference
values in Norway [10].
Maternal preeclampsia was defined as increased blood pres-
sure to>140/90 mmHg and proteinuria after 20 weeks of gesta-
tion [11]. We did not have an access to information about the
severity or onset of preeclampsia. We defined pregestational
maternal disease as maternal diabetes mellitus, kidney disease,
rheumatic disease or essential hypertension diagnosed before
pregnancy. Malformations in the newborns had been recorded
as present if any malformation had been observed before dis-
missal from the hospital; in the statistical analyses, a dichoto-
mous variable was used.
Outcome variables
The outcome was development of ESRD and onset defined
as the date of starting dialysis treatment or undergoing renal
transplantation. Subjects with kidney failure who did not receive
chronic dialysis treatment or kidney transplantation were not
recorded as having an outcome. Subjects who did not develop
ESRD were followed until 31 December 2016 or date of death.
Causes of ESRD were divided into five categories: glomerular
diseases, interstitial diseases, congenital or hereditary disease
(congenital kidney or urinary tract malformations, cystic kidney
disease and other heritable causes of renal disease), diabetic ne-
phropathy and other causes (hypertensive nephropathy, renal
vascular disease, tumours, rare causes and unknown cause).
Statistical analyses
Data were analysed in a cohort design with birth-related var-
iables for the subject as exposure variables and ESRD as the
outcome variable. Hazard ratio (HR) estimates were obtained
by Cox regression statistics, start of follow-up was set at the
date of birth. Participants with missing data were not included
in the statistical analyses. Birth weight was missing for 0.09% of
included participants and gestational age was missing for 4.3%.
Adjusted analyses were performed for the main analyses by in-
cluding birth year, gender (male versus female), maternal dis-
ease (yes versus no), maternal preeclampsia (yes versus no),
maternal marital status (single versus non-single) and malfor-
mations in the newborn (yes versus no) in the statistical analy-
ses. Risks after 18 years of age were analysed separately.
Analyses using different gender-specific cut-offs for birth
weight and z-score and gender stratified analyses were
performed.
Because no cases with ESRD had been registered between
1967 and 1979, subjects born in this period were left truncated
in the survival analyses before January 1980. Consequently, the
counting process formulation of proportional hazards (Cox re-
gression) was applied. This method does not include index sub-
jects in the analysis until an event could be registered, i.e. a
subject born in 1973 would be included in the analyses at
7 years of age and right censored at age 43 years if he/she did
not develop ESRD or died.
If not otherwise stated, values are reported as means
(SD), or HR estimates with 95% confidence intervals (CIs)
are given; P< 0.05 was considered statistically significant
and all tests were two-tailed. The analyses were performed
using the STATA SE Edition 15.1 statistical package
(StataCorp).
R E S U L T S
Study participants
A total of 2 679 967 individuals were included in this
study and 1181 of these developed ESRD during follow-up at
a mean age of 27.9 6 11.5 years. The mean age at ESRD was
26.5 6 13.0 years for LBW and 27.5 6 11.9 years for SGA.
Characteristics of included individuals are shown in Table 1.
In Supplementary data, Table S1, we have shown character-
istics according to birth weight percentile. Individuals who
later developed ESRD more often had LBW (16.1% versus
10%), SGA (15.5% versus 10%) or preterm birth (7.3% versus
4.8%) as compared with individuals who did not develop
ESRD (Supplementary data, Table S2).
Risk associated with birth-related variables
At ages 10, 20, 30, 40 and 50 years, 0.0037, 0.014, 0.040,
0.083 and 0.14%, respectively, of included individuals had de-
veloped ESRD. Compared with individuals with birth weight
above the 10th percentile, LBW was associated with an in-
creased HR of 1.68 (1.44–1.97) for development of ESRD
(Table 2). Corresponding HRs for individuals with SGA was
1.49 (1.27–1.75), for preterm birth 1.65 (1.31–2.07), for birth
weight < 2.5 kg 2.0 (1.59–2.56) and for maternal preeclampsia
HR was 1.53 (1.12–2.08). Results were largely the same in males
and females, except for preterm birth, which was not signifi-
cantly associated with ESRD in females.
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In Table 2, we observed higher HR for LBW if defined by
birth weight <2.5 kg as compared with LBW defined by <10th
percentile (2.94 kg for males and 2.85 kg for females). We there-
fore decided to investigate possible dose–response relationships
for LBW and LBW for gestation age. In these analyses, we cate-
gorized birth weight and birth weight for gestational age
according to gender-specific percentiles and the following
groups were analysed: below 5th percentile, 5–10th, 10–20th,
20–80th (reference), 80–90th, 90–95th and above the 95th per-
centile cut-offs. Dose–response relationships were observed
both for LBW and birth weight for gestational age with higher
risks for lower birth weights and non-significant trends for
lower risk in the 90–95th percentile groups (Table 3). There
was, however, a difference as the 5–10th percentile groups were
only significant for LBW (P ¼ 0.001) and not for birth weight
for gestational age (P ¼ 0.1). When these analyses were strati-
fied for gender, we observed that the risk of ESRD was increased
at the 5–10th percentile both for men and for women in LBW
(P ¼ 0.001 and 0.045, respectively). When these analyses were
stratified by maternal preeclampsia, we observed that maternal
preeclampsia did not impact this risk.
Risks associated with combinations of LBW, SGA and
preterm birth
To further analyse the different effects of LBW, SGA and
preterm birth, we investigated how combinations of these varia-
bles associated with risk of ESRD. Compared with individuals
who had been born at term without LBW and SGA, having
been born at term with SGA and LBW [adjusted HR (aHR) ¼
1.71 (1.41–2.09)], having been born preterm with LBW but
without SGA [aHR ¼ 1.54 ¼ (1.11–2.13)] and having been
born preterm with LBW and SGA [aHR ¼ 2.96 (1.84–4.76)]
were associated with increased risk of ESRD (Table 4). Based on
these results, we chose to perform an analysis in which we
counted the risk markers (LBW, SGA and preterm birth).
Compared with individuals with zero risk markers, individuals
Table 1. Characteristics of participants
Characteristic LBW (<10th percentile) SGA (<10th percentile)
No Yes No Yes
Total number 2 408 569 270 217 2 306 286 257 156
Number with ESRD 990 191 932 183
Number with ESRD per 1 000 000 participants follow-up year 17.0 29.89 16.27 25.96
Mean 6 SD duration follow-up, years 25.26 6 14.35 25.61 6 14.50* 24.84 6 14.48 27.41 6 14.5*
Mean 6 SD age at ESRD, years 28.29 6 11.17 26.53 6 13.0 28.08 6 11.39 27.57 6 11.92
Mean 6 SD parity 0.95 6 1.07 0.78 6 1.07* 0.96 6 1.07 0.72 6 1.01*
Mean 6 SD birth weight, g 3656 6 435 2517 6 421* 3626 6 490 2729 6 379*
Mean 6 SD z-score 0.136 6 1.21 1.38 6 1.16* 0.18 6 0.2 1.8 6 0.46*
Mean 6 SD gestational age, weeks 39.94 6 1.57 37.29 6 3.13* 39.69 6 1.93 39.53 6 2.1*
Preterm birth (%) 1.78 3.1* 4.63 6.42*
Apgar score 5 min <7 (%) 0.75 2.89* 0.9 1.65*
Maternal preeclampsia (%) 2.21 8.87* 2.47 6.52*
Maternal diseasea (%) 2.32 3.31* 2.37 2.74*
Congenital malformations (%) 2.86 4.67* 2.99 3.78
Congenital malformations of kidney or urinary tract (%) 0.10 0.15* 0.10 0.12
aMaternal disease defines as pregestational diabetes mellitus, kidney or urinary tract disease, rheumatic disease or essential hypertension.
*P< 0.001.
Table 2. HR for ESRD according to birth-related variables
Risk marker Unadjusted Adjusteda
All All Men Women
n HR (95% CI) P-value HR (95% CI) P-value n HR (95% CI) P-value n HR (95% CI) P-value
Birth weight <10th
percentile
No 981 1.0 (ref) 1.0 (ref) 628 1.0 (ref) 353 1.0 (ref)
Yes 191 1.68 (1.44–1.97) <0.001 1.61 (1.38–1.88) <0.001 118 1.55 (1.27–1.89) <0.001 73 1.71 (1.33–2.27) <0.001
Z-score <10th percentile No 932 1.0 (ref) 1.0 (ref) 592 1.0 (ref) 330 1.0 (ref)
Yes 183 1.49 (1.27–1.75) <0.001 1.44 (1.23–1.69) <0.001 116 1.46 (1.19–1.79) <0.001 67 1.40 (1.07–1.82) 0.013
Preterm birth No 1100 1.0 (ref) 1.0 (ref) 698 1.0 (ref) 405 1.0 (ref)
Yes 81 1.65 (1.31–2.07) <0.001 1.54 (1.22–1.92) <0.001 58 1.64 (1.25–2.15) <0.001 23 1.32 (0.86–2.01) 0.2
Birth weight <2.5 kg No 1109 1.0 (ref) 1.0 (ref) 710 1.0 (ref) 399 1.0 (ref)
Yes 72 2.0 (1.59–2.56) <0.001 1.91 (1.50–2.43) <0.001 43 1.86 (1.36–2.54) <0.001 29 1.98 (1.35–2.90) <0.001
Maternal preeclampsia No 1139 1.0 (ref) 1.0 (ref) 725 1.0 (ref) 414 1.0 (ref)
Yes 42 1.53 (1.12–2.08) 0.006 1.48 (1.09–2.02) 0.012 28 1.52 (1.04–2.22) 0.029 14 1.41 (0.82–2.41) 0.203
aAdjusted for birth year, gender, maternal disease (defines as maternal diabetes mellitus, kidney disease, rheumatic disease or essential hypertension diagnosed before pregnancy), ma-
ternal preeclampsia, maternal marital status and malformations in the newborn.
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with one risk marker did not have increased risk of ESRD [aHR
¼ 1.05 (0.84–1.31)], individuals with two risk markers had an
increased risk with aHR ¼ 1.67 (1.40–1.98) and individuals
with three risk markers had an increased risk with aHR ¼ 2.96
(1.84–4.76). Figure 1 illustrates the same finding but also illus-
trates that the groups separate in adult age.
Risk factors for ESRD due to different causes
Among the 1181 individuals who developed ESRD, 486 de-
veloped ESRD as a result of glomerular disease, 113 as a result
of interstitial disease, 303 as a result of congenital or inherited
disease, 187 as a result of diabetic nephropathy and 144 due to
other causes. Corresponding numbers for individuals who de-
veloped ESRD after 18 years of age were 406, 96, 172, 157 and
129. Table 5 shows risk for specific causes of ESRD according to
the three different main risk markers: LBW, SGA and preterm
birth.
For individuals with ESRD due to hereditary or developmen-
tal disease, age at ESRD was lower for subjects with LBW as
compared with subjects with normal birth weight (19.2 versus
24.0 years; P¼ 0.01). For other causes of ESRD, age at ESRD was
similar, i.e. 26.7 versus 27.6 years (P¼ 0.5) for glomerular dis-
ease, 29.8 versus 28.6 years (P¼ 0.7) for interstitial disease, 36.0
versus 36.8 years (P¼ 0.6) for diabetic nephropathy and 34.1
versus 31.8 years (P ¼ 0.3) for other kidney disease.
We observed the strongest risk estimates for ESRD due to
hereditary or developmental diseases, but risks were otherwise
similarly associated with the different causes of ESRD. There is
a possibility that congenital urinary tract malformations and
hereditary renal disease might be a cause of low weight. We
therefore decided to repeat the main analyses in Table 4 using
ESRD due to other causes than hereditary or congenital disease
as the outcome variable. In these analyses, we observed almost
identical HRs as we did in the analyses of the adult age group
Table 3. Risk of ESRD for different percentile cut-offs for birth weight and birth weight for gestational age, separate analyses stratified for gender
Risk marker All Men Women
Total, n ESRD, n HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Birth weight
<5th percentile 135 599 105 1.89 (1.53–2.32) <0.001 1.84 (1.38–2.36) <0.001 2.04 (1.47–2.83) <0.001
5–10th percentile 134 809 86 1.48 (1.18–1.85) 0.001 1.48 (1.12–1.96) 0.006 1.46 (1.00–2.13) 0.045
10–20th percentile 270 389 130 1.10 (0.91–1.33) 0.3 1.24 (0.98–1.55) 0.047 0.86 (0.61–1.22) 0.4
20–80th percentile 1 615 278 667 1.0 (ref) 1.0 (ref) 1.0 (ref)
80–90th percentile 258 169 97 0.97 (0.78–1.20) 0.8 0.98 (0.75–1.28) 0.9 0.94 (0.66–1.35) 0.8
90–95th percentile 129 163 39 0.80 (0.58–1.10) 0.2 0.89 (0.61–1.31) 0.6 0.62 (0.34–1.13) 0.1
>95th percentile 132 049 48 0.98 (0.73–1.32) 0.9 0.79 (0.52–1.20) 0.3 1.29 (0.84–1.98) 0.2
Birth weight for gestational age (z-score)
<5th percentile 129 628 111 1.74 (1.42–2.12) <0.001 1.68 (1.30–2.18) <0.001 1.84 (1.33–2.54) <0.001
5–10th percentile 127 528 72 1.20 (0.94–1.54) 0.1 1.33 (1.00–1.82) 0.06 1.00 (0.65–1.55) 0.9
10–20th percentile 261 890 121 1.03 (0.85–1.26) 0.7 1.06 (0.83–1.36) 0.6 1.02 (0.74–1.40) 0.9
20–80th percentile 1 534 279 624 1.0 (ref) 1.0 (ref) 1.0 (ref)
80–90th percentile 256 637 95 0.96 (0.77–1.19) 0.7 1.03 (0.80–1.34) 0.9 0.83 (0.57–1.23) 0.4
90–95th percentile 12 140 36 0.75 (0.54–1.06) 0.1 0.80 (0.53–1.20) 0.3 0.68 (0.38–1.22) 0.2
>95th percentile 126 340 56 1.16 (0.88–1.53) 0.3 1.05(0.73–1.50) 0.8 1.34 (0.87–2.06) 0.2
Table 4. HR for ESRD according to whether the individuals had LBW, SGA or were born preterm
Risk marker Total follow-up period Age 18–50 years
Total, n ESRD, n aHRa (95% CI) P-value Total, n ESRD, n aHRa (95% CI) P-value
Term, not SGA or LBW 2 162 166 851 1.0 (ref) 1 348 384 689 1.0 (ref)
Term, SGA, not LBW 100 971 52 1.01 (0.76–1.34) 0.9 74 138 44 1.03 (0.76–1.40) 0.8
Term, not SGA, LBW 34 160 11 0.89 (0.50–1.61) 0.7 18 793 6 0.60 (0.27–1.34) 0.3
Term, SGA and LBW 139 520 113 1.71 (1.41–2.09) <0.001 96 560 87 1.56 (1.24–1.96) <0.001
Preterm, not SGA or LBW 40 909 23 1.26 (0.83–1.91) 0.3 28 252 18 1.20 (0.76–1.93) 0.3
Preterm, SGA, not LBW No data No data No data
Preterm, not SGA, LBW 65 631 38 1.54 (1.11–2.13) 0.009 37 335 28 1.41 (0.97–2.06) 0.07
Preterm, SGA and LBW 16 482 18 2.96 (1.84–4.76) <0.001 9624 12 2.44 (1.36–4.35) 0.003
Number of risk factorsb
0 2 162 166 851 1.0 (ref) 1 348 384 689 1.0 (ref)
1 176 040 86 1.05 (0.84–1.31) 0.7 121 183 68 1.00 (0.78–1.29) 0.9
2 205 151 151 1.67 (1.40–1.98) <0.001 133 895 115 1.52 (1.25–1.85) <0.001
3 16 482 18 2.96 (1.84–.76) <0.001 9624 12 2.44 (1.37–4.34) 0.003
aAdjusted for birth year, gender, maternal disease (defines as maternal diabetes mellitus, kidney disease, rheumatic disease or essential hypertension diagnosed before pregnancy), ma-
ternal preeclampsia, maternal marital status and malformations in the newborn. bNumber of the risk factors LBW (defined by <10th percentile), SGA (defined by <10th percentile)
and preterm birth (<37 weeks).
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18–50 years (right part of Table 4), i.e. slightly lower risk esti-
mates than for all-cause ESRD.
D I S C U S S I O N
This study showed that LBW was associated with a 70% in-
creased risk and SGA was associated with a 50% increased risk
for development of ESRD during the first 50 years of life. Some
previous studies have observed that males are more affected by
LBW than females [2, 6, 9, 12], but we observed no gender differ-
ence in our study. The most novel finding was, however, that
none of the risk markers LBW, SGA or preterm birth was associ-
ated with risk of ESRD if present alone; at least two of the risk
markers needed to be present in order to see an increased risk.
This importantly narrows the cohort with increased risk that
might need further follow-up. As the number of individuals with
ESRD has doubled since the last Norwegian studies [7, 8], this
study offers more certain analyses of gender differences, combi-
nation of risk markers and different cut-offs for LBW and SGA.
Our study supports previous studies [2, 4, 9, 13, 14] that
there is a significant association between markers of intrauter-
ine growth such as LBW, SGA and prematurity and later devel-
opment of ESRD in adult age. The risk was increased for all
causes of ESRD and this supports the Brenner hypothesis that
impaired nephron endowment with lower glomerular number
and compensatory larger glomeruli lead to increased risk of
progression in any kidney disease [1, 25, 26, 28]. The plausible
mechanisms of impaired nephron endowment, and thus which
risk marker is more important, has been discussed in several
studies [7, 9, 15, 16, 27]. Eriksson et al. reported that LBW and
prematurity were associated with CKD in older people [9] and
recently Crump et al. showed that prematurity was an impor-
tant risk marker for CKD before the age of 20 years, but that
there did not seem to be an increased risk after the age of
20 years [27]. The relative importance of the different risk
markers thus seems to change with age. LBW is the most acces-
sible and used marker of adverse intrauterine environment and
it results from either intrauterine growth restriction or preterm
birth [5]. Intrauterine growth restriction is measured in our
study as birth weight for gestational age, but could also be mea-
sured during pregnancy by clinical examination or ultrasonog-
raphy. Our study confirms the findings of previous studies that
LBW, SGA and preterm birth are associated with increased risk
for kidney disease in adult age [7, 8], and all risk markers
seemed to be important. Previous studies have shown that com-
bination of these risk markers increases risk further [17]. We
found the same in this study, but we also showed that partici-
pants who only had one of the risk markers LBW, SGA or pre-
term birth did not have an increased risk. This has never been
shown before and should be investigated further. Studies have
argued that all subjects with either LBW, SGA or preterm birth
should have some sort of follow-up to detect early kidney dis-
ease [3, 18], which according to our study would constitute
15.6% of the population (Table 4). Importantly, this could be re-
duced to 8.6% by including only subjects with at least two of the
risk markers. More studies are needed to investigate this associ-
ation in other populations and to address the potential cost ver-
sus benefit of such follow-up. As most developing countries
define low birth weight <2.5 kg and often have imprecise data
for gestational age and SGA, our results should be used with
caution in such settings. It should also be mentioned that our
data only discuss risk of severe kidney disease and that screen-
ing for cardiovascular risk factors such as hypertension and dia-
betes mellitus might be beneficial also in individuals with only
one risk marker.
There seems to be a dose–response relationship between the
severity of preterm birth, LBW or SGA and risk of kidney dis-
ease in adult age. In our main analyses, we have defined LBW
and SGA as less than the 10th percentile in order to have suffi-
cient numbers of outcomes in subgroups. In both this and
























FIGURE 1: Risk of ESRD according to number of birth-related risk
factors (birth weight <10th percentile, birth weight for gestational
age <10th percentile and preterm birth).
Table 5. HR for different causes of ESRD according to birth characteristics
Risk marker Glomerular disease Interstitial disease Hereditary/ developmental disease Diabetic nephropathy Other renal diseases
n HR (95% CI) n HR (95% CI) n HR (95% CI) n HR (95% CI) n HR (95% CI)
Birth weight
<10th percentile
No 421 1.0 (ref) 95 1.0 (ref) 239 1.0 (ref) 159 1.0 (ref) 113 1.0 (ref)
Yes 65 1.33 (1.03–1.74) 15 1.36 (0.80–2.35) 61 2.26 (1.70–3.00) 28 1.50 (1.00–2.25) 28 2.12 (1.40–3.21)
Z-score <10th
percentile
No 385 1.0 (ref) 90 1.0 (ref) 234 1.0 (ref) 148 1.0 (ref) 116 1.0 (ref)
Yes 79 1.56 (1.23–1.99) 15 1.26 (0.73–2.18) 51 1.70 (1.25–2.31) 27 1.32 (0.88–1.99) 22 1.41 (0.89–2.31)
Preterm birth No 466 1.0 (ref) 107 1.0 (ref) 274 1.0 (ref) 173 1.0 (ref) 132 1.0 (ref)
Yes 20 0.96 (0.61–1.50) 6 1.25 (0.55–2.83) 29 2.32 (1.60–3.41) 14 1.82 (1.06–3.14) 12 2.04 (1.13–3.70)
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cut-off of 2.5 kg yielded higher risk estimates [19]. In this study,
we explored the association between different cut-offs for LBW
and SGA and risk of developing ESRD; further more, we also
investigated possible gender differences that have been sug-
gested by other studies [6, 12]. For both LBW and SGA, HRs in-
creased with lower cut-offs and was statistically significant at
lower than the 10th percentile for LBW but only for less than
the 5th percentile for SGA. Overall, these analyses supported
the use of the 10th percentile cut-off for LBW but one could ar-
gue that the 5th percentile should be used for SGA. As all previ-
ous studies investigating SGA have used the 10th percentile [7,
20–22], we have decided to do the same. Use of the 10th percen-
tile for LBW in Norway defined all newborns with a birth
weight of <2.8–2.9 kg as LBW. Our study cannot answer
whether this cut-off, the WHO cut-off of 2.5 kg or the national
10th percentile should be used to identify newborns at risk in
other populations. A major challenge is selection of an appro-
priate global reference [20]. LBW could be a marker of intra-
uterine growth restriction, but in an international context it
could also include newborns who are small due to genetic fac-
tors, maternal smoking or maternal undernutrition. Prevalence
of offspring with birth weight <2.5 kg is for example very high
in South Asia, but it is unknown whether these data represent
true growth restriction or normal development of smaller off-
spring [14]. At the same time, using the 10th percentile cut-off
might be problematic in populations affected by undernutri-
tion, in which the cut-off should preferably be defined in sub-
populations without undernutrition.
The major strength of our study is the opportunity to use the
national registries to include a large number of participants
with prospective registration of birth-related variables and
near-complete follow-up. Compared with a previous
Norwegian study from 2016 [8], we have in this study a much
larger number of included subjects. This was mostly due to
follow-up until 2016 (versus 2009) and inclusion of the whole
population (versus only those with at least one sibling). One
limitation is that ESRD was not registered between 1967 and
1980, and the counting processes of Cox regression were there-
fore used for statistical analyses and likely compensated this
limitation. The study population is mostly Caucasian so results
might be different in other populations groups. Another limita-
tion is that ESRD is a rare endpoint, and even though we in-
cluded 2.7 million participants, only 1181 developed ESRD.
This is, however, twice the number as compared with our
previous studies [7, 8]. Potential confounders could be low
socio-economic status, smoking, educational level and ethnic
origin. We did not have access to these data in our study but
we were able to adjust for single versus non-single mother,
which is a socio-economic marker. A weakness is also that we
had no information on diseases diagnosed after the prenatal
period and could therefore not adjust for diseases developed
in adulthood.
In conclusion, we have shown that markers of LBW are asso-
ciated with development of ESRD during the first 50 years of
life. Our study also showed that the risk markers LBW, SGA
and preterm birth may not be associated with development of
ESRD if present alone. Furthermore, our study investigated cut-
offs for LBW and SGA and suggested that using the 10th per-
centile could be the best, but it is still uncertain which cut-offs
are the best in other populations. We suggest that our results
should be investigated further in other populations and prefera-
bly also using lower CKD stages as outcomes. Early detection of
individuals with high risk of kidney disease would allow for
early intervention to delay disease progression and the most
clinically relevant might be screening for hypertension, diabetes
mellitus and proteinuria [3, 23, 24]. Our study indicates that
this might be beneficial in persons with at least two of the risk
factors LBW, SGA or preterm birth.
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A B S T R A C T
Background. Zinc deficiency is commonly encountered in
chronic kidney disease (CKD). The aims of this study were to
assess whether zinc deficiency was related to increased renal ex-
cretion of zinc and to the progression of CKD.
Methods. Plasma and 24-h urinary zinc levels, urinary electro-
lytes and uromodulin were measured in 108 CKD patients and
81 individuals without CKD. Serum creatinine values were col-
lected for 3 years to calculate the yearly change in estimated glo-
merular filtration rate (eGFR). Multivariable regression analysis
was performed to assess the association between baseline zinc
levels and yearly change in eGFR.
Results. CKD patients had lower circulating zinc levels and
higher 24-h urinary zinc excretion than non-CKD participants
(612.4 6 425.9 versus 479.2 6 293.0mg/day; P¼ 0.02). Fractio-
nal excretion (FE) of zinc was higher and it significantly in-
creased at more advanced CKD stages. Zinc FE was correlated
negatively with 24-h urinary uromodulin excretion (r¼0.29;
P< 0.01). Lower baseline plasma zinc levels were associated
with a faster yearly decline of renal function in age, gender, dia-
betes and hypertension adjusted models, but this relationship
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